Over the past 12 months, $SLS has been discussed by 5 distinct FinTwit voices across 25 mentions, with the first mention appearing on December 26, 2025. Dustin (@dustinhuntwn) has been the most active voice discussing the ticker with 12 mentions, followed by InvestmentGuru (@investmentguru_) and Vulture trades (@vulturetrades) each contributing 5 mentions. Adam Feuerstein (@adamfeuerstein) and Cobra (@cobraalerts) have contributed 2 and 1 mentions respectively. The long research category represents the most active discussion category for Sellas Life Sciences Group.

The most recent discussion occurred on July 17, 2026, when Adam Feuerstein noted that "$SLS is a $3B company now, which has a LMAA tinge to it. 34% short interest currently, third highest among biotechs." Earlier commentary from Feuerstein on May 27, 2026 centered on the company's management team touting delayed mortality events in its Phase 3 study, with Feuerstein stating "I have not paid attention to $SLS at all, but I see its management team is touting the delayed arrival of the last death event required to zip up its Phase 3 study as a positive indication of success."